CliffBio
small molecule

CEFOTAXIME

CEFOTAXIME SODIUM

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameCEFOTAXIME
Active ingredientCEFOTAXIME SODIUM
StrengthEQ 10GM BASE/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalMarch 2000
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.